Ultragenyx Pharmaceutical Inc.
Narrative signal
Ultragenyx Pharmaceutical Inc.’s revenue growth stands at 29% for Dec 2024. Year-over-year, the metric shifted by +9.5 pts, translating into a +48.63% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Ultragenyx Pharmaceutical Inc. trades at $36.38 with a market footprint around $3.5B.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 29%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. (RARE) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Ultragenyx Pharmaceutical Inc. (RARE) stock price today?
Ultragenyx Pharmaceutical Inc. (RARE) trades near $36.38 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Ultragenyx Pharmaceutical Inc.'s market capitalization?
Ultragenyx Pharmaceutical Inc.'s equity is valued around $3.5B, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc.'s 52-week range runs from $25.81 — $50.00. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Ultragenyx Pharmaceutical Inc. stock?
Ultragenyx Pharmaceutical Inc. most recently moved about 1.2M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Ultragenyx Pharmaceutical Inc. pay a dividend?
Ultragenyx Pharmaceutical Inc. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Ultragenyx Pharmaceutical Inc.'s intraday trading range?
Ultragenyx Pharmaceutical Inc. has traded between $35.94 — $37.25 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Ultragenyx Pharmaceutical Inc. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Ultragenyx Pharmaceutical Inc. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.